| Popis: |
Background Hyperandrogenism has been described with different frequencies in populations of women and adolescents with type 1 diabetes (T1D). Ethnic differences account for variation in genetic causes as well as clinical and metabolic parameters for diagnosis. We aimed to evaluate clinical, laboratory and imaging tests of a sample of adult women with T1D in order to calculate a valid sample size for further studies in our population, which presents a high prevalence of metabolic syndrome. Materials and methods we included the first patients from a group of 55 women with T1D between the ages of 18 and 45. Blood samples were performed in the early follicular phase and ultrasound in the follicular phase. Ferriman-Gallwey score was evaluated by two independent trained observers. We excluded patients with hysterectomy or oophorectomy or continuous use of hormonal contraceptives in the last 3 months or previous cosmetic treatments. Non-parametric tests were calculated using SPSS v 21. 0 with a p Results 27 women had full workup, their median age was 32 years (IQR 25-40), the age of diagnostic of T1D was 13.5 years (IQR 10-20), 55.5% had a BMI >25 kg/m2, HbA1c was 8.6% (IQR 7.3-10) and used 0.83 UI insulin/kg/day (IQR 0.62-1. 06). Using the Rotterdam criteria 40.7% had PCOS, and 33.3% by stricter criteria based in hyperandrogenemia (AE-PCOS and NIH). A Ferriman-Gallwey score of 9 or higher was agreed in 40.7% of the cases with a inter-observer kappa of 77% (p 2. 0ng/mL, and 1 with undiagnosed primary ovarian insufficiency. A sample size of 41 is needed to achieve a power of 80% in this setting. Insulin doses were higher in patients with SOP compared with other patients (1. 06IU/kg/day in patients with PCOS and 0.73IU/kg/day in patients without PCOS, p=0. 013, IC -0.59; -0. 07). Discussion and conclusions Our population shows a high frequency of hyperandrogenism, which affects the patients reproductive capabilities, but also may be related to adverse metabolic outcomes. Hyperandrogenism may be related to PCOS, but also to undiagnosed comorbidities, which require further endocrine evaluation. More awareness is needed in the diagnosis of these conditions in our population. Presentation: No date and time listed |
